10 Atrial Fibrillation Clinical Trials in Duarte, CA (2026)

Q: How do I join a clinical trial in Duarte?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you.

Recruiting Atrial Fibrillation Studies in Duarte

NCT04710576Recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host diseas...

Duarte, CAPHASE2296 participantsSyndax Pharmaceuticals

View Study Details

NCT06585774Recruiting

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGV...

Duarte, CAPHASE3240 participantsIncyte Corporation

View Study Details

NCT04380740Recruiting

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

This is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosi...

Duarte, CAPHASE2160 participantsBoston Children's Hospital

View Study Details

NCT06936566Recruiting

MAGIC Ruxolitinib for aGVHD

This clinical trial will study ruxolitinib-based treatment of acute graft-versus-host-disease (GVHD) that developed following allogeneic hematopoietic cell transplant. Acute GVHD occurs when donor cel...

Duarte, CAPHASE298 participantsJohn Levine

View Study Details

NCT05996627Recruiting

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem ...

Duarte, CAPHASE282 participantsFred Hutchinson Cancer Center

View Study Details

NCT06343792Recruiting

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the second...

Duarte, CAPHASE266 participantsReAlta Life Sciences, Inc.

View Study Details

NCT07124078Recruiting

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

This study will be conducted to compare Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy....

Duarte, CAPHASE260 participantsIncyte Corporation

View Study Details

NCT06619561Recruiting

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in...

Duarte, CAPHASE248 participantsDeciphera Pharmaceuticals, LLC

View Study Details

NCT05443425Recruiting

Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

This phase I trial tests the safety and side effects of leflunomide in combination with steroids in treating patients with acute graft versus host disease who have undergone done stem cell transplant ...

Duarte, CAPHASE118 participantsCity of Hope Medical Center

View Study Details

NCT03975231Recruiting

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and tram...

Duarte, CAPHASE16 participantsCity of Hope Medical Center

View Study Details

About Atrial Fibrillation Clinical Trials in Duarte

Atrial fibrillation (AFib) is the most common type of heart arrhythmia, causing an irregular and often rapid heartbeat. It significantly increases the risk of stroke, heart failure, and other complications. Treatment includes blood thinners, heart rate or rhythm control medications, and procedures like ablation.

There are currently 10 atrial fibrillation clinical trials recruiting participants in Duarte, CA. These studies are seeking a combined 1,074 participants. Research is being sponsored by Syndax Pharmaceuticals, Incyte Corporation, Boston Children's Hospital and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atrial Fibrillation Clinical Trials in Duarte — FAQ

Are there atrial fibrillation clinical trials in Duarte?

Yes, there are 10 atrial fibrillation clinical trials currently recruiting in Duarte, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Duarte?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you about next steps.

Are clinical trials in Duarte free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Duarte studies also compensate for your time and travel.

What atrial fibrillation treatments are being tested?

The 10 active trials in Duarte are testing new therapies including novel drugs, biologics, and treatment approaches for atrial fibrillation.

Data updated September 2, 2026 from ClinicalTrials.gov